A Recombinant Human Adenovirus Type 5 (H101) Combined With Chemotherapy for Advanced Gastric Carcinoma: A Retrospective Cohort Study

BackgroundThis retrospective cohort study aimed to evaluate the clinical outcomes of H101 combined with chemotherapy for advanced gastric carcinoma (GC) patients. MethodsThe advanced GC patients, who were treated with H101 and/or chemotherapy, were enrolled and divided into three groups according to treatment method. The clinical characteristics of patients, clinical short-term and long-term outcomes, followed up, and complication were analyzed. ResultsA total of 95 patients (30 patients in group A were treated with H101, 33 in group B patients were treated with chemotherapy, 32 patients in group C were treated with H101 combined with chemotherapy) were retrospectively reviewed. The disease control rate (DCR) and overall response rate (ORR) were significantly greater in group C (81.3% and 50.0%) than in groups A (63.3% and 30.0%) and B (66.7% and 33.3%, all p < 0.05). The 1- and 2-year survival rates and progression-free survival were significantly greater in group C than in groups A and B (all p < 0.05). There was no significant difference in complication among the three groups. At dose levels of 0.5 x 10(12) vp/day, 1.0 x 10(12) vp/day, and 1.5 x 10(12) vp/day, complications were not increased as increased of dose. ConclusionsH101 combined with chemotherapy may be a potential therapeutic option for patients with advanced GC, and prospective studies with proper assessment of toxicity will be needed in the future.

Automated summary

This study suggests that H101 combined with chemotherapy may be a potential therapeutic option for patients with advanced gastric carcinoma, with significantly improved disease control rate, overall response rate, and survival rates compared to chemotherapy or H101 alone. Additionally, complications did not increase with higher doses of treatment. Further prospective studies with proper assessment of toxicity are needed in the future.